This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NK NantKwest (NK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About NantKwest Stock (NASDAQ:NK) 30 days 90 days 365 days Advanced Chart Get NantKwest alerts:Sign Up Key Stats Today's Range$2.66▼$2.8150-Day Range$16.09▼$38.7052-Week Range$2.52▼$45.42Volume15.46 million shsAverage Volume1.57 million shsMarket Capitalization$295.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Read More… Receive NK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter. Email Address NK Stock News HeadlinesPiper Sandler Upgrades ImmunityBio (IBRX)May 21, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy RecommendationMarch 7, 2025 | msn.comAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.June 30 at 2:00 AM | Paradigm Press (Ad)Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger TreatmentsFebruary 4, 2025 | seekingalpha.comBTIG Initiates Coverage of ImmunityBio (IBRX) with Buy RecommendationJanuary 11, 2025 | msn.comSpace Nk Promo CodesFebruary 4, 2024 | time.comTFrankie Bridge shares her new Space NK beauty buys including concealer people 'love'August 13, 2023 | mirror.co.ukMPiper Sandler Downgrades ImmunityBio (IBRX)May 13, 2023 | msn.comSee More Headlines NK Stock Analysis - Frequently Asked Questions How were NantKwest's earnings last quarter? NantKwest, Inc. (NASDAQ:NK) issued its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative trailing twelve-month return on equity of 56.06% and a negative net margin of 76,658.58%. When did NantKwest IPO? NantKwest (NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager. What other stocks do shareholders of NantKwest own? Based on aggregate information from My MarketBeat watchlists, some other companies that NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Dynavax Technologies (DVAX) and OPKO Health (OPK). Company Calendar Last Earnings5/11/2020Today6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NK CIK1326110 Webwww.nantkwest.com Phone858-633-0300FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.79 million Net Margins-76,658.58% Pretax MarginN/A Return on Equity-56.06% Return on Assets-46.93% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual Sales$40 thousand Price / Sales7,380.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book2.20Miscellaneous Outstanding Shares109,345,000Free FloatN/AMarket Cap$295.23 million OptionableNot Optionable Beta2.61 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:NK) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.